Phathom Pharmaceuticals, Inc. (PHAT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 5 Margin 5 Expansion 3 Platform 2 Financial 3

latest quarter score

Earnings Reports

18
Fathom Pharmaceuticals (PHAT) Q2 2026: Operating Profit Turns Positive as Revenue Jumps 88%, GI-First Strategy Delivers
July 30, 2026
16
Fathom Pharmaceuticals (PHAT) Q1 2026: New-to-Brand Share Hits 45% Among Top GI Prescribers, Reinforcing First-Mover Advantage
April 30, 2026
15
Fathom Pharmaceuticals (PHAT) Q4 2025: Revenue Jumps 217% as GI Focus Drives Prescription Adoption
February 27, 2026
17
Fathom (PHAT) Q3 2025: 43% Cut in Cash Opex Reshapes Path to 2026 Profitability
October 30, 2025
17
Fathom (PHAT) Q2 2025: 39% Revenue Jump Anchors GI-First Pivot and Cost Reset
August 07, 2025
12
Fathom Pharmaceuticals (PHAT) Q1 2025: $60M OpEx Cut Targets 2026 Profit Amid Voquezna Growth
July 04, 2025
Phathom Pharmaceuticals (PHAT) Q4 2024: VOQUEZNA Prescriptions Double to 300,000, Accelerating Market Penetration
March 06, 2025

Browse all companies